Cas no 1160269-99-7 (2-Naphthalenecarboxylic acid, 4-hydroxy-7-[4-(trifluoroMethyl)phenyl]-, ethyl ester)

2-Naphthalenecarboxylic acid, 4-hydroxy-7-[4-(trifluoromethyl)phenyl]-, ethyl ester is a specialized organic compound featuring a naphthalene core substituted with a hydroxyl group at the 4-position and a 4-(trifluoromethyl)phenyl moiety at the 7-position, esterified with ethanol. This structure imparts unique physicochemical properties, including enhanced lipophilicity and stability due to the trifluoromethyl group, making it valuable in synthetic chemistry and pharmaceutical research. The ethyl ester functionality improves solubility in organic solvents, facilitating its use as an intermediate in the synthesis of more complex molecules. Its well-defined aromatic and fluorinated components may also contribute to applications in materials science, particularly in the development of advanced polymers or fluorescent probes.
2-Naphthalenecarboxylic acid, 4-hydroxy-7-[4-(trifluoroMethyl)phenyl]-, ethyl ester structure
1160269-99-7 structure
Product Name:2-Naphthalenecarboxylic acid, 4-hydroxy-7-[4-(trifluoroMethyl)phenyl]-, ethyl ester
CAS No:1160269-99-7
MF:C20H15F3O3
MW:360.326516389847
CID:832557
Update Time:2026-04-29

2-Naphthalenecarboxylic acid, 4-hydroxy-7-[4-(trifluoroMethyl)phenyl]-, ethyl ester Chemical and Physical Properties

Names and Identifiers

    • 2-Naphthalenecarboxylic acid, 4-hydroxy-7-[4-(trifluoroMethyl)phenyl]-, ethyl ester
    • Ethyl 4-hydroxy-7-[4-(trifluoromethyl)phenyl]-2-naphthoate
    • 4-hydroxy-7-trifluoromethyl-quinoline-3-carboxylic acid ethyl ester
    • 4-keto-7-(trifluoromethyl)-1H-quinoline-3-carboxylic acid
    • 7-trifluoromethyl-4-hydroxyquinoline-3-carboxylic acid ethyl ester
    • BUTTPARK 21�9-47
    • ethyl 4-hydroxy-7-trifluoromethyl-3-quinolinecarb
    • ETHYL 4-HYDROXY-7-TRIFLUOROMETHYL-3-QUINOLINECARBOXYLATE
    • ethyl 4-hydroxy-7-trifluoromethylquinoline-3-carboxylate
    • ethyl 7-(4-(trifluoromethyl)phenyl)-4-hydroxy-2-naphthoate
    • Inchi： InChI=1S/C20H15F3O3/c1-2-26-19(25)15-10-14-9-13(5-8-17(14)18(24)11-15)12-3-6-16(7-4-12)20(21,22)23/h3-11,24H,2H2,1H3
    • InChI Key： QHKJMDBQTKSCQG-UHFFFAOYSA-N
    • SMILES： CCOC(=O)C1=CC(=C2C=CC(=CC2=C1)C3=CC=C(C=C3)C(F)(F)F)O

Computed Properties

  • Hydrogen Bond Donor Count: 1
  • Hydrogen Bond Acceptor Count: 3
  • Heavy Atom Count: 26
  • Rotatable Bond Count: 5

2-Naphthalenecarboxylic acid, 4-hydroxy-7-[4-(trifluoroMethyl)phenyl]-, ethyl ester Pricemore >>

Related Categories No. Product Name Cas No. Purity Specification Price update time Inquiry
abcr
AB591505-100mg
4-Hydroxy-7-[4-(trifluoromethyl)phenyl]-2-naphthalenecarboxylic acid ethyl ester; .
 1160269-99-7
100mg
 €3502.30 2024-07-20

2-Naphthalenecarboxylic acid, 4-hydroxy-7-[4-(trifluoroMethyl)phenyl]-, ethyl ester Related Literature

Additional information on 2-Naphthalenecarboxylic acid, 4-hydroxy-7-[4-(trifluoroMethyl)phenyl]-, ethyl ester

Research Brief on 2-Naphthalenecarboxylic acid, 4-hydroxy-7-[4-(trifluoroMethyl)phenyl]-, ethyl ester (CAS: 1160269-99-7)

The compound 2-Naphthalenecarboxylic acid, 4-hydroxy-7-[4-(trifluoroMethyl)phenyl]-, ethyl ester (CAS: 1160269-99-7) has recently garnered significant attention in the field of chemical biology and pharmaceutical research. This molecule, characterized by its naphthalene core and trifluoromethylphenyl substituent, exhibits unique physicochemical properties that make it a promising candidate for various therapeutic applications. Recent studies have focused on its synthesis, structural optimization, and biological evaluation, particularly in the context of inflammation and cancer research.

One of the key areas of investigation has been the compound's potential as a modulator of inflammatory pathways. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that this ethyl ester derivative exhibits potent inhibitory activity against cyclooxygenase-2 (COX-2), an enzyme implicated in inflammatory diseases. The researchers employed molecular docking simulations to elucidate the binding interactions between the compound and the COX-2 active site, revealing a high affinity driven by hydrophobic interactions with the trifluoromethylphenyl group.

In addition to its anti-inflammatory properties, recent preclinical studies have explored the anticancer potential of 1160269-99-7. A research team from the University of Cambridge reported in Bioorganic & Medicinal Chemistry Letters that this compound induces apoptosis in certain cancer cell lines by disrupting mitochondrial membrane potential. The study highlighted the role of the 4-hydroxy group in enhancing the compound's bioavailability and cellular uptake, which could be leveraged for further structural modifications to improve therapeutic efficacy.

From a synthetic chemistry perspective, advances have been made in the scalable production of 2-Naphthalenecarboxylic acid, 4-hydroxy-7-[4-(trifluoroMethyl)phenyl]-, ethyl ester. A recent patent (WO2023056123) describes a novel catalytic method for its synthesis, achieving higher yields and purity compared to traditional routes. This development is particularly significant for industrial-scale production, addressing previous challenges related to cost and reproducibility.

Despite these promising findings, challenges remain in the clinical translation of this compound. Pharmacokinetic studies indicate that while the ethyl ester moiety improves membrane permeability, it may also lead to rapid metabolism in vivo. Current research efforts are focused on prodrug strategies and formulation technologies to overcome these limitations. The compound's unique chemical structure continues to serve as a valuable scaffold for the development of new chemical entities with enhanced therapeutic profiles.

In conclusion, 2-Naphthalenecarboxylic acid, 4-hydroxy-7-[4-(trifluoroMethyl)phenyl]-, ethyl ester represents an exciting area of research in medicinal chemistry. Its dual anti-inflammatory and anticancer activities, coupled with recent synthetic advancements, position it as a compound of significant interest for future drug development. Ongoing studies are expected to further elucidate its mechanism of action and optimize its pharmacological properties for clinical applications.

1160269-99-7 (2-Naphthalenecarboxylic acid, 4-hydroxy-7-[4-(trifluoroMethyl)phenyl]-, ethyl ester) Related Products

Recommended suppliers
TAIXING JOXIN BIO-TEC CO.,LTD.
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
TAIXING JOXIN BIO-TEC CO.,LTD.
Shanghai Hongxiang Biomedical Technology Co., Ltd.
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Shanghai Hongxiang Biomedical Technology Co., Ltd.
Hebei Liye chemical Co.,Ltd
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Hebei Liye chemical Co.,Ltd
Zhengzhou Baoyu Pharmaceutical Co., Ltd.
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Zhengzhou Baoyu Pharmaceutical Co., Ltd.
Zhangzhou Sinobioway Peptide Co.,Ltd.
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Reagent
Zhangzhou Sinobioway Peptide Co.,Ltd.